TREATMENT OF OVARIAN CANCER USING AN ANTICANCER AGENT CONJUGATED TO AN ANGIOPEP-2 ANALOG
    7.
    发明申请
    TREATMENT OF OVARIAN CANCER USING AN ANTICANCER AGENT CONJUGATED TO AN ANGIOPEP-2 ANALOG 有权
    使用与ANGIOPEP-2模拟相结合的ANTICANCER AGENT治疗OVARIAN癌症

    公开(公告)号:US20120122798A1

    公开(公告)日:2012-05-17

    申请号:US13265309

    申请日:2010-04-20

    摘要: Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an ammo acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2.

    摘要翻译: 用抗癌剂和Angiopep-2多肽类似物(即包含与Seq.ID NO:97至少80%相同的氨基酸序列的多肽)的缀合物处理卵巢癌。 这种治疗包括治疗转移性卵巢癌和治疗先前对标准化学治疗剂具有抗性的患者的效用。 优选的抗癌剂包括紫杉烷,而优选的缀合物是ANG1005,包含与肽Angiopep-2缀合的三分子紫杉醇的缀合物。

    SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF
    8.
    发明申请
    SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF 审中-公开
    用于治疗结合物的短和含氨基酸的多肽及其用途

    公开(公告)号:US20130280281A1

    公开(公告)日:2013-10-24

    申请号:US13807640

    申请日:2011-07-04

    IPC分类号: C07K7/08 C07K16/00 C07K7/06

    摘要: The present invention relates to short polypeptides (e.g., fewer than 19 amino acids in length) and longer polypeptides (e.g., 19 or more amino acids in length) having one or more D-amino acids as targeting moieties. These polypeptides, when conjugated to agents (e.g., therapeutic agents or transport vectors) are capable of transporting the agents across the BBB or into particular cell types. In particular, the short polypeptides can include one or more D-amino acids. These compounds are therefore particularly useful in the treatment of neurological diseases or diseases associated with particular cell types, organs, or tissues.

    摘要翻译: 本发明涉及具有一个或多个D-氨基酸作为靶向部分的短多肽(例如,长度上少于19个氨基酸)和更长的多肽(例如,长度为19个或更多个的氨基酸)。 当与试剂(例如治疗剂或转运载体)缀合时,这些多肽能够将该药物转运穿过BBB或特定的细胞类型。 特别地,短多肽可以包括一个或多个D-氨基酸。 因此,这些化合物特别可用于治疗与特定细胞类型,器官或组织相关的神经疾病或疾病。

    FUSION PROTEINS FOR DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM
    10.
    发明申请
    FUSION PROTEINS FOR DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM 审中-公开
    用于将GDNF和BDNF递送至中央神经系统的融合蛋白

    公开(公告)号:US20120196803A1

    公开(公告)日:2012-08-02

    申请号:US13377480

    申请日:2010-06-11

    摘要: The present invention relates to a compound that includes a peptide vector, such as angiopep-2 which acts as a carrier across the blood-brain barrier, linked to glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), or a related molecule, such as an analog or a fragment thereof. The compounds of the invention may be used to treat any disease where increased neuronal survival or growth is desired, e.g., neurodegenerative diseases, such as Parkinson's disease or amyotrophic lateral sclerosis. Other diseases can be treated using the compounds include schizophrenia and depression.

    摘要翻译: 本发明涉及一种化合物,其包含肽载体,例如作用于血脑屏障的载体的血管紧张素-2,与神经胶质来源的神经营养因子(GDNF),脑源性神经营养因子(BDNF), 或相关分子,例如其类似物或片段。 本发明的化合物可用于治疗需要增加神经元存活或生长的任何疾病,例如神经变性疾病,例如帕金森病或肌萎缩性侧索硬化症。 可以使用包括精神分裂症和抑郁症在内的化合物治疗其他疾病。